Searched over 200M research papers
5 papers analyzed
These studies suggest that lisinopril is beneficial for improving insulin sensitivity in non-diabetic hypertensive patients, reducing risks in congestive heart failure, protecting kidney function in non-diabetic chronic renal diseases, and may improve sperm count in infertile males, indicating its multifaceted therapeutic effects beyond blood pressure control.
18 papers analyzed
Lisinopril is a widely used ACE inhibitor primarily prescribed for conditions such as hypertension, congestive heart failure (CHF), and chronic renal insufficiency. It has demonstrated significant benefits in improving heart function, reducing blood pressure, and slowing the progression of renal diseases . However, patients may seek alternatives due to side effects or specific health conditions.
Losartan, an angiotensin II receptor antagonist, is a notable alternative to lisinopril. Both medications effectively reduce systolic and diastolic blood pressure. However, they differ in their impact on insulin sensitivity. Lisinopril significantly improves insulin sensitivity, as indicated by increased glucose infusion rates and total glucose requirements. In contrast, losartan does not significantly affect insulin sensitivity.
In a study comparing the two drugs, both lisinopril and losartan significantly reduced blood pressure, but lisinopril had a more pronounced effect on insulin sensitivity. This makes lisinopril a preferable option for hypertensive patients with concerns about insulin resistance.
Captopril and enalapril are other ACE inhibitors that have been compared with lisinopril. In clinical trials, lisinopril was found to be at least as effective as captopril and enalapril in improving symptomatic endpoints and clinical status in patients with CHF. Lisinopril also demonstrated a better tolerance profile, especially in patients with renal impairment .
Lisinopril has shown specific renoprotective effects in patients with chronic renal insufficiency, particularly those with mild proteinuria. It significantly slows the decline in renal function compared to other antihypertensive agents, making it a superior choice for patients with chronic kidney disease.
Irbesartan, another angiotensin II receptor antagonist, has been compared with lisinopril in the treatment of CHF. Both drugs were found to be effective, but lisinopril had a slight edge in improving left ventricular ejection fraction (LVEF) and exercise duration. Additionally, lisinopril was well tolerated, with a similar adverse event profile to irbesartan .
Lisinopril has also been studied for its effects on male infertility, specifically idiopathic oligospermia. When combined with zinc-folic acid, lisinopril significantly improved sperm concentration and total motile sperm count compared to zinc-folic acid alone. This suggests that lisinopril may have additional benefits beyond its cardiovascular and renal effects.
While lisinopril remains a highly effective and well-tolerated ACE inhibitor for various conditions, alternatives such as losartan, captopril, enalapril, and irbesartan offer viable options depending on patient-specific needs and tolerability. Each alternative has its unique benefits and limitations, making it essential to tailor treatment plans to individual patient profiles.
Most relevant research papers on this topic